Background Very limited labelled indications have been approved for the newer antimicrobials and extensively drug-resistant gram-positive bacterial infections that are a clinical challenge.
Purpose Data on the clinical uses, efficacy and safety of dalbavancin, a novel lipoglycopeptide, in real life is scarce, thus we sought to describe our clinical experience.
Material and methods Descriptive study of patients treated with dalbavancin from June 2016 to September 2017 in a tertiary hospital in southern Spain.
Results Twenty-two patients were involved. Demographics, microbiology, therapy characteristics, adverse events and clinical outcomes are described in table 1. Eighty-six per cent were used under off-label indications in patients who had tried and/or failed other therapies.
Conclusion Further evidence beyond labelled indications is urgently needed. Despite the limitations, in our clinical practice, the use of dalbavancin under multidisciplinary antimicrobial stewardship team supervision appears to be a promising, safe and effective option for adult patients who have tried and/or failed other therapies due to multidrug-resistant gram-positive organisms and/or may offer added safety and potential cost reductions.
References and/or acknowledgements No conflict of interest.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.